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Prospective Study of 114 Consecutive Episodes of Staphylococcus 
aureus Bacteremia 
Joseph M. Mylotte, Carolyn McDermott, 
and Jody A. Spooner 
From the Division of Infectious Diseases, Department of 
Medicine and the Department of Microbiology, State 
University of New York at Buffalo; and the Veterans 
Administration Medical Center, Buffalo, New York 
From 1 April 1983 to 31 October 1985, 114 episodes of Staphylococcus aureus bacteremia 
(SAB) were identified in 111 patients at the Buffalo Veterans Administration Medical 
Center. Only 14% of the episodes were community-acquired, and 29% were due to 
methicillin-resistant strains. The commonest foci of SAB were intravascular catheters (33%), 
postoperative wounds (11%), skin infections (7%), and pulmonary infections (7%o). Com- 
plications were infrequent, with endocarditis in two patients and metastatic infection in 
one. Mortality due to SAB was 32%, with no difference in mortality between community- 
acquired and hospital-acquired SAB. Although not statistically significant, there was a 
trend of higher mortality for methicillin-resistant SAB (42%0) than for methicillin-sensitive 
SAB (28%o) and for patients with no focus of SAB (43%) than for those with a defined 
primary focus (28%). A review of studies of SAB published since 1940 revealed several 
trends. SAB is now predominately a nosocomial infection; intravascular-catheter infec- 
tion has become the commonest cause of SAB; with several exceptions, the risk of en- 
docarditis in patients with SAB is low (50/-20%0); mortality due to SAB has decreased 
over the past 40 years but not over the past 10 years. 
Staphylococcus aureus was recently characterized by 
Sheagren [1] as the "persistent pathogen." Despite 
the availability of potent antistaphylococcal antibi- 
otics, infection due to S. aureus continues to cause 
considerable morbidity and mortality [2-4]. The 
most serious result of infection is S. aureus bacter- 
emia (SAB). 
Since 1940 many studies have been published deal- 
ing with SAB in general hospital populations [5-25]. 
Only three of these studies [18, 19, 21] were per- 
formed prospectively. In one of these studies [19], 
which was performed by one of us (J. M. M.), 49 
consecutive episodes of SAB were followed at two 
hospitals. Although this study provided useful in- 
formation, the number of patients evaluated was rel- 
atively small and the findings may not have neces- 
sarily represented the overall picture of SAB at either 
hospital. 
In the current study the results of a 30-month 
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prospective evaluation of all cases of SAB that oc- 
curred at the Veterans Administration Medical Cen- 
ter (VAMC) in Buffalo, New York, are reported. Our 
specific objectives included, but were not limited to: 
(1) determination of the risk of endocarditis in the 
subset of patients with community-acquired SAB in 
whom it has been retrospectively noted [15] that there 
is a high risk of endocarditis; (2) extension of a previ- 
ous report [19] regarding the overall risk of endocar- 
ditis and metastatic infection in patients with SAB; 
and (3) evaluation of the types of infections produc- 
ing SAB, with the intent of defining possible preven- 
tive measures. We also review studies of SAB pub- 
lished after 1940. 
Methods and Definitions 
All of the patients evaluated in this study were inpa- 
tients at the VAMC in Buffalo, New York. Two pa- 
tients with a diagnosis of SAB who were transferred 
to the Buffalo VAMC from other institutions were 
not included in this study. The Buffalo VAMC is a 
628-bed, tertiary-care, university-affiliated hospital 
with an additional 106 beds designated for long-term 
care. The Buffalo VAMC provides acute medical and 
surgical care; there are separate medical and surgi- 
cal intensive care units. The VAMC also provides ep- 
arate services for oncology, hemodialysis, rehabili- 
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tation medicine, drug detoxification, psychiatry, 
neurology, and geriatrics. 
Patients with SAB were identified by frequent 
monitoring of the blood-culture log book in the mi- 
crobiology laboratory during the period from 1 April 
1983 to 31 October 1985. During the study period 
blood cultures were performed by injecting 5-10 mL 
of blood into a commercial two-bottle media sys- 
tem (BACTEC; Johnson Laboratories, Towson, Md. 
21204). S. aureus was identified by use of standard 
microbiologic criteria. Antimicrobial susceptibility 
testing was performed by use of the disk diffusion 
method [26]. The detection of methicillin-resistant 
S. aureus (MRSA) strains was performed by suscep- 
tibility tests at 35?C for 48 hours [27]. Cultures of 
other body fluids and sites were performed in the 
usual manner. Intravenous catheter tips were cultured 
by use of the semiquantitative technique of Maki et 
al. [28]. 
SAB. Patients were considered to have SAB if 
two or more blood cultures were positive for S. aureus 
within a 24-hour period, or one blood culture was 
positive for S. aureus and the clinical course was con- 
sistent with staphylococcal infection. SAB was con- 
sidered community-acquired if the first positive 
blood culture was obtained within 72 hours of ad- 
mission or if there was clinical and cultural evidence 
of S. aureus infection at a body site at the time of 
admission. SAB was considered hospital-acquired if 
the first positive blood culture was obtained >72 
hours after admission and no clinical evidence of 
infection (fever, leukocytosis, signs, or symptoms) 
was present on admission. 
Primary and secondaryfoci of SAB. A localized 
focus of staphylococcal infection was considered the 
source (primary focus) of SAB if signs and symp- 
toms of infection or confirmatory physical findings 
antedated the bacteremia. Foci of staphylococcal in- 
fection in the CNS or joints were always considered 
to be secondary foci unless there was evidence of di- 
rect inoculation (surgery or trauma). A peripheral 
iv catheter was considered the focus of SAB if there 
was no other focus of infection identified and one 
or more of the following was present: inflammation 
at the site of insertion of the catheter; purulent drain- 
age from the insertion site that on culturing, grew 
S. aureus; or a semiquantitative culture of the cath- 
eter [28] that was positive for S. aureus. A central 
venous catheter was considered to be the source of 
SAB if there was no other focus of infection and one 
or more of the following applied: the catheter had 
been in place for at least 72 hours, semiquantitative 
catheter culture was positive for S. aureus, or there 
was purulent drainage from the insertion site that, 
on culturing, grew S. aureus. 
Endocarditis. Patients with SAB and one or 
more of the following were considered to have en- 
docarditis: pathologic evidence of endocarditis at au- 
topsy; a murmur in diastole, a new or changing mur- 
mur, or a characteristic regurgitant murmur; a 
murmur plus embolic phenomena; or evidence of 
endocarditis at operation confirmed by histologic ex- 
amination. 
Antibiotic treatment. The final decision as to the 
specific antibiotic prescribed and the duration of 
therapy was the responsibility of the primary care 
physician. 
Outcome. Five categories of outcome were de- 
fined. (1) Death due to SAB. Patient deaths were at- 
tributed to staphylococcal infection if one or more 
of the following criteria pertained in the absence of 
another explanation for death: positive blood cul- 
tures for S. aureus at the time of death; a persistent 
focus of staphylococcal infection at death; persis- 
tent signs or symptoms of infection such as fever, 
leukocytosis, or hypotension; or death within the first 
7 days of documentation of SAB without another 
explanation. (2) Death due to underlying disease dur- 
ing treatment of SAB. Patient deaths were attributed 
to underlying disease(s) during treatment of SAB if 
all of the following pertained: repeat blood cultures 
were sterile and there was evidence of control of in- 
fection manifested by resolution of or resolving fe- 
ver, leukocytosis, and signs and symptoms at a spe- 
cific body site and the underlying disease(s) was of 
a severity that death might be expected. (3) Recov- 
ery from SAB but ultimate death from underlying 
disease during the same admission. Patients were 
placed in this category if death occurred due to a 
defined underlying disease(s) after completion of 
therapy for SAB (with resolution of symptoms and 
signs of infection). (4) Recovered from SAB but re- 
mained hospitalized. Patients in this category suc- 
cessfully completed a course of therapy for SAB, but 
remained hospitalized due to other medical prob- 
lems. (5) Recovery from SAB and discharged. Pa- 
tients in this category successfully completed ther- 
apy for SAB and were discharged from the hospital. 
By use of the aforementioned efinitions, patients 
with SAB were observed and the following informa- 
tion was tabulated: age, hospital service, underlying 
diseases, primary focus of infection, development 
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of complications (e.g., metastatic infection, endocar- 
ditis), antibiotic(s) administered, duration of ther- 
apy, and outcome. Each patient was followed until 
death occurred from SAB or underlying disease dur- 
ing the course of antibiotic therapy; in those patients 
who successfully completed therapy, follow-up was 
continued until discharge or for a maximum of 4 
weeks after therapy in those who remained hospital- 
ized. However, because complications of SAB may 
not be manifest for several weeks after discontinua- 
tion of therapy [29], the inpatient and outpatient 
records of all patients who completed therapy were 
reviewed after completion of the study to determine 
if there were any delayed complications. 
Determination of the yearly frequency of SAB at 
the Buffalo VAMC and comparison with the yearly 
frequency of bacteremia due to other organisms was 
carried out by a review of the blood-culture log books 
from 1977 through 1985. By use of a microcomputer 
and data management software, the following infor- 
mation was tabulated for each patient with positive 
blood cultures: social security number, date of the 
cultures, ward location, number of blood-culture sets 
performed, number of blood-culture bottles that 
demonstrated bacterial growth, organism(s) isolated, 
and susceptibility-test results. If a patient had posi- 
tive blood cultures for the same organism on several 
successive days, this was counted as only one bac- 
teremic episode unless the period of time between 
positive cultures was >7 days. For this analysis the 
presence of any Enterobacteriaceae, Pseudomonas 
species, and anaerobic bacteria in blood cultures was 
considered to represent a true bacteremia. Isolation 
of coagulase-negative staphylococci from a partic- 
ular patient was considered to represent contamina- 
tion unless blood cultures performed on at least two 
separate days were positive and the organisms were 
detected within 48 hours of blood-culture inocula- 
tion [30]. Isolation of S. aureus in blood cultures was 
considered to document a true bacteremia in a par- 
ticular patient if two or more sets of blood cultures 
drawn on the same day were positive or if single 
blood-culture sets drawn on several successive days 
were positive. The finding of S. aureus isolates that 
took >48 hours to grow or of only one positive bot- 
tle among one or more sets of cultures was consid- 
ered to represent contamination. For the purpose of 
the present report, only data on the yearly rate of 
bacteremia for various bacterial species will be 
reported. 
Comparisons of clinical characteristics were per- 
formed by %2 analysis. Analysis of the rates of bac- 
teremia over time was performed by linear regres- 
sion. A P value of <.05 was considered significant. 
Studies of SAB in adults that were published from 
1940 on were reviewed. The review included studies 
in which pediatric patients as well as adult patients 
were evaluated. However, studies dealing specifically 
with pediatric patients, cancer or hemodialysis pa- 
tients, outbreaks of SAB, or only with bacteremia 
due to MRSA were not included. For each study 
reviewed, particular attention was paid to primary 
foci of SAB, complications, and mortality. 
Results 
The results of the review of the blood-culture log 
books are given in table 1 along with hospital demo- 
graphic information for the period 1 January 1977- 
31 December 1985. Increases in the yearly number 
Table 1. Annual rates of blood-culture processing and bacteremia at the Buffalo Veterans Administration Medical 
Center, 1977-1985. 
No. of blood- No. of Blood-culture 
culture sets episodes of No. of sets processed/ Bacteremia/ 
Year processed bacteremia discharges 1,000 discharges 1,000 discharges 
1977 4,399 172 12,404 354.6 13.9 
1978 4,996 204 12,427 402.0 16.4 
1979 4,744 181 12,186 389.3 14.9 
1980 5,939 222 14,516 409.1 15.3 
1981 5,172 199 13,563 381.3 14.7 
1982 5,374 174 13,003 413.3 13.4 
1983 6,500 224 13,649 476.2 16.4 
1984 5,507 218 14,552 378.4 15.0 
1985 5,997 224 14,403 416.4 15.6 
Mean + SD 5,392 + 682 202 + 22 13,411 + 951 402 ? 3.5 15.1 + 1.0 
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Table 2. Rate of bacteremia for the six most commonly isolated microorganisms at the Buffalo Veterans Adminis- 
tration Medical Center, 1977-1985. 
No. of episodes of bacteremia with indicated organism/10,000 discharges 
Staphylococcus Escherichia Streptococcus Klebsiella Proteus Pseudomonas 
Year aureus coli pneumoniae pneumoniae mirabilis aeruginosa 
1977 16.1 28.2 11.3 8.1 8.1 8.1 
1978 18.5 29.0 17.7 16.1 15.3 7.3 
1979 22.1 31.1 8.2 9.8 10.7 8.2 
1980 20.0 31.7 18.6 12.4 11.0 3.4 
1981 16.9 28.7 11.1 15.4 13.2 8.1 
1982 21.5 26.2 16.2 11.5 14.6 7.7 
1983 37.5 35.3 14.0 16.9 14.0 7.4 
1984 28.1 36.3 13.0 15.8 8.9 8.9 
1985 28.5 24.3 12.5 11.8 10.4 10.4 
NOTE. The correlation coefficient (r) for each organism was: S. aureus, + .730 (P < .05); E. coli, + .106; S. pneumoniae, 
- .001; K. pneumoniae, + .401; P. mirabilis, - .004; and P. aeruginosa, + .407. 
of episodes of bacteremia detected and in hospital 
discharges paralleled the gradual increase in the 
yearly number of blood cultures processed during 
this period. However, the yearly rate of bacteremia 
showed little variation during the same period, with 
an average (? SD) of 15.1 + 1.0 episodes of bacter- 
emia per 1,000 discharges. 
The six bacterial species most commonly isolated 
from blood cultures between 1977 and 1985 are listed 
in table 2 along with the yearly rate of isolation of 
each organism per 10,000 hospital discharges. Al- 
though there was some variation in the yearly rate 
of bacteremia due to Escherichia coli, Streptococcus 
pneumoniae, Klebsiella pneumoniae, Proteus mira- 
bilis, and Pseudomonas aeruginosa, simple linear 
regression revealed no significant increase or decrease 
in the individual rates of bacteremia during the 9- 
year study period. However, there was a significant 
increase in the rate of SAB during the same period. 
Analysis of the yearly frequency of SAB is shown 
in table 3; the increase in frequency of SAB began 
in 1983 and was, in part, due to the appearance of 
episodes due to MRSA strains. 
Characteristics of Patients with SAB 
During the 30 months of this study, 121 patients were 
found to have S. aureus in blood cultures. Ten pa- 
tients were excluded because the S. aureus found in 
their blood cultures was felt to represent contami- 
nation. From these 10 patients, only one blood cul- 
ture bottle (of one or more sets from each patient) 
grew S. aureus; none of the patients had an obvious 
focus of infection. The remaining 111 patients had 
114 episodes of SAB. Three patients had two sepa- 
rate episodes of SAB. 
Sixteen (14%) of the 114 episodes of SAB were 
community acquired. All but three patients were 
male, a finding consistent with the population stud- 
ied. No primary focus was identified for six (38%) 
of 16 episodes of community-acquired SAB and 17 
(17%) of 98 hospital-acquired episodes. Thirty (26%) 
episodes of SAB were due to MRSA; all of these epi- 
sodes were hospital acquired. The mean age (? SD) 
of the 111 patients was 64.6 + 11.5 years; only five 
patients were younger than 50 years. There was no 
significant difference in the mean age of patients 
with methicillin-susceptible SAB (MSSAB) and 
MRSA bacteremia (MRSAB)-64.6 + 11.5 and 65.5 
+ 11.0 years, respectively. All but two patients had 
at least one significant underlying disease. There was 
Table 3. Annual frequency of Staphylococcus aureus 
bacteremia t the Buffalo Veterans Administration Medi- 
cal Center, 1977-1985. 
No. of episodes 
Year MSSA* MRSA* Total 
1977 20 0 20 
1978 23 0 23 
1979 27 0 27 
1980 29 0 29 
1981 23 0 23 
1982 26 2 28 
1983 39 12 51 
1984 34 7 41 
1985 29 12 41 
* MSSA = methicillin-sensitive S. aureus; MRSA = methi- 
cillin-resistant S. aureus. 
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Table 4. Foci of infection and selected characteristics of 114 episodes of Staphylococcus aureus bacteremia. 
No. of episodes with indicated characteristic 
Acquisition Total no.Acquis Due to Death due Total no. 
Focus of episodes Community Hospital MRSA to SAB of deaths 
Intravascular catheter 38 1 37 11 9 18 
Wound 13 0 13 4 4 4 
Skin 8 3 5 3 2 2 
Lung 8 1 7 2 6 6 
Decubitus ulcer 5 2 3 1 2 3 
Genitourinary tract 4 0 4 0 0 2 
Pacemaker 3 0 3 1 0 0 
Arteriovenous hunt 3 0 3 0 0 0 
Bone 2 1 1 1 0 1 
Peritonitis 2 1 1 1 11 
Orthopedic pin 1 0 1 1 0 0 
Biliary tract 1 1 0 0 0 0 
Mediastinum 1 0 1 0 1 1 
Joint 2 0 2 0 1 1 
Unknown 23 6 17 5 10 13 
Total 114 16 98 30 36 52 
NOTE. Abbreviations: MRSA = methicillin-resistant S. aureus; SAB = S. aureus bacteremia. 
an average of 1.9 diseases per patient, and the per- 
centage of patients with each disease was as follows: 
alcoholism (19%), malignant solid tumors (17%), 
coronary artery disease (14%), chronic renal failure 
(13%), cirrhosis (13%), diabetes (12%), chronic lung 
disease (11%), and hematologic cancers (5%). 
Foci of SAB 
The primary foci of SAB are given in table 4. The 
single commonest primary focus was an infected iv 
catheter. These cases are discussed in more detail be- 
low. SAB secondary to pneumonia was associated 
with the highest mortality rate (75%). Patients in 
whom no focus was identified had an overall mor- 
tality rate of 42%. Infections of the lung, skin, and 
soft tissue and those due to iv catheters, wounds, 
and unknown foci accounted for 80% (91 of 114) 
of all episodes of SAB; 80 (887o) of these 91 epi- 
sodes were hospital-acquired infections. In this group 
of 91 patients, the relation between the focus of SAB 
and underlying disease was analyzed. Five (63%) of 
eight patients with skin or soft tissue infection were 
diabetic; three (38%) of eight patients with pneu- 
monia had cancer; 14 (37%o) of 38 patients with in- 
travascular catheter infection had cancer; and eight 
(35%) of 23 patients with an unidentified focus of 
SAB had cirrhosis. For all foci except wound infec- 
tions, SAB occurred more commonly on the medi- 
cal service than the surgical service; overall, 63 epi- 
sodes of SAB occurred on the medical service, 
whereas 18 occurred on the surgical service. The re- 
maining 23 episodes occurred on several other ser- 
vices, with no one service predominating. 
There were 38 episodes of SAB due to an infected 
intravascular catheter. Twenty-eight of these cases 
have been previously reported [31]. There were 20 
peripheral-catheter infections, of which 18 were lo- 
cated in peripheral veins in the upper extremities, one 
in the radial artery, and one in the femoral vein. 
Eighteen subclavian vein catheters became infected; 
16 were standard central venous catheters, and two 
were Hickman catheters. The criteria used to make 
a diagnosis of intravascular catheter-associated SAB 
are given in table 5. Nine (24%) of 38 patients died 
as a direct result of catheter-induced SAB. In these 
nine patients the duration of therapy before death 
ranged from 0 to 11 days. There was no clinical evi- 
dence of endocarditis in any of these nine patients. 
However, endocarditis was suspected in one patient 
with a prosthetic aortic valve and metastatic lung 
cancer in whom SAB developed secondary to an in- 
fected peripheral catheter. After 1 day of therapy, 
the patient died, but an autopsy was not performed. 
Because of the high risk of endocarditis in patients 
with SAB and a prosthetic valve, it was presumed 
that endocarditis was present. An autopsy was per- 
formed on only one of the other eight patients who 
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died, and no evidence of endocarditis was noted. Five 
other patients with catheter-associated SAB died of 
their underlying disease during the same admission 
after recovering from the SAB, and three patients 
died of their underlying disease while receiving treat- 
ment for SAB. Autopsies were not performed on 
these latter eight patients; none had clinical evidence 
of endocarditis. Thus, the overall mortality rate in 
this group of patients was 45% (17 of 38). For the 
26 patients who recovered, the mean duration of an- 
tibiotic therapy was 13.8 days (range, 5-28 days). Only 
five patients received treatment for >21 days. No com- 
plications were noted in this group of 26 patients. 
Bacteremia with MRSA 
During the study period 30 episodes of MRSAB oc- 
curred in 28 patients. The foci of infection of these 
30 episodes included an iv catheter in 11, an unknown 
site in five, skin in three, a wound in four, the lung 
in two, and miscellaneous sites in five. The mortal- 
ity rate due to MRSAB was 42%. Mortality was 
higher on the surgical service (six deaths [55%] in 
11 episodes) than the medical service (four deaths 
[29%] in 14 episodes; P > .1 by X2). Although this 
difference was not statistically significant, it was large 
enough to warrant evaluation of the initial antibi- 
otic therapy prescribed. This evaluation revealed that 
10 (71%) of 14 patients on the medical service re- 
ceived vancomycin as initial therapy, while six (55%) 
of 11 patients on the surgical service received van- 
comycin initially; this difference was not significant 
(P >.10). 
The relation of antibiotic therapy prescribed to 
outcome of MRSAB was also analyzed. Although 
the mortality rate in patients receiving vancomycin 
with or without a second agent was lower (32%; six 
of 19) than the mortality rate in patients who received 
therapy that did not include vancomycin (50%; three 
of six), this difference was not statistically signifi- 
cant. These findings suggested that outcome for pa- 
tients with MRSAB was improved when vancomy- 
cin was part of the therapeutic regimen. Since only 
slightly more than 50% of the patients with MRSAB 
on the surgical service received vancomycin, this may 
explain, in part, the higher mortality in this group. 
The lack of significant improvement in the mortal- 
ity rate among patients with MRSAB treated with 
vancomycin may be due to the small number of pa- 
tients in the analysis. 
A secondary focus of infection was identified in 
Table 5. Criteria used to make a diagnosis of intra- 
vascular-catheter-associated Staphylococcus aureus bac- 
teremia (SAB). 
No. of patients with 
infection of indicated 
type of catheter* 
Peripheral Central venous 
Criterion (n = 20) (n = 18) 
Inflammation with no other 
focus of SAB 16 0 
Purulent drainage from 
insertion site 3 8 
Semiquantitative catheter 
culture (no. positive/ 
no. cultured) 1/1 12/12 
No other focus of SABt 0 3 
* Some patients had more than one criterion and as a result 
the numbers add up to more than the number of episodes. 
t No inflammation or drainage; no catheter culture performed. 
only one patient. He was a 66-year-old man who un- 
derwent an open reduction and internal fixation of 
a fractured acetabulum. Ten days after surgery an 
infection developed at the insertion site of the pin 
being used for internal fixation. Drainage from 
around the pin as well as blood cultures grew MRSA. 
The pin was removed and the patient received 2 weeks 
of vancomycin therapy despite the recommendation 
by an infectious diseases consultant for 4 weeks of 
parenteral therapy. Nine weeks after therapy was dis- 
continued, the patient developed fever and was read- 
mitted. Gallium scan and computed tomography of 
the vertebral skeleton revealed changes consistent 
with osteomyelitis at the L4-L5 level. Blood cultures 
again yielded MRSA. He was treated with vancomy- 
cin and rifampin for 3 weeks and was discharged to 
a nursing home. Our belief that the vertebral bone 
was seeded during the first episode of SAB and rep- 
resented a secondary focus is based on the absence 
of an intercurrent illness that would have been as- 
sociated with bacteremia and recurrence of MRSA 
in blood cultures. 
Endocarditis in Patients with SAB 
The diagnosis of endocarditis was made in only two 
of the 111 patients with SAB. One of the patients 
with a prosthetic heart valve and SAB was described 
in a previous section. The other patient was a 71- 
year-old man with a history of stroke who was ad- 
mitted with fever and confusion. Blood cultures per- 
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formed at the time of admission grew S. aureus, but 
no focus of infection was identified. The patient was 
treated iv with nafcillin. A lumbar puncture was per- 
formed on the fifth day of hospitalization, and cul- 
tures of the CSF yielded a few colonies of S. aureus. 
The dose of nafcillin was increased from 6 g to 12 
g on the sixth day of hospitalization. The patient died 
on the seventh day of hospitalization with intractable 
hypotension, acidosis, and persistent fever and leuko- 
cytosis. Autopsy revealed acute endocarditis of the 
mitral valve with multiple infarcts in the kidneys and 
spleen. 
Outcome of SAB 
Thirty-six (32%) of 111 patients died due to SAB; 
four of the 36 patients received no treatment, and 
three of the four died within 24 hours after blood 
cultures were performed. For the remaining 32 pa- 
tients, SAB was determined to be the cause of death 
on the basis of the following criteria: persistently 
positive blood cultures (two patients), persistent fo- 
cus of staphylococcal infection (11 patients), persis- 
tent signs and symptoms of infection (15 patients), 
and death within 7 days of the first positive blood 
culture for which there was no other explanation 
(four patients). Only two autopsies were performed: 
one patient was found to have acute endocarditis of 
the mitral valve as previously detailed, and the other 
had no evidence of endocarditis or metastatic infec- 
tion. In addition to the 36 patients who died as a 
direct result of SAB, 17 others died either of an un- 
derlying disease after successful treatment of SAB 
(n = 10) or of underlying disease during treatment 
(n = 7). Autopsies were performed on three of these 
17 patients, and none had evidence of endocarditis. 
Fifty-eight patients with 59 episodes of SAB re- 
covered; 24 of these patients remained hospitalized 
for 4 weeks after which follow-up was stopped, and 
34 of the patients were discharged. Of the 34 patients 
who were discharged, all but four left the hospital 
within 7 days of discontinuation of antibiotic treat- 
ment for SAB. In order to determine if there were 
late complications of SAB, especially in those dis- 
charged, follow-up was sought in these 58 patients 
by retrospective review of hospital and clinic records 
after completion of the study in October 1985. This 
follow-up was performed in January 1986. No charts 
were available for 14 patients, but review of data from 
the medical administrative service of the VAMC re- 
vealed that three of the 14 were subsequently dis- 
charged, seven died during the same hospital admis- 
sion in which SAB occurred, and there was no 
information for the remaining four patients. Another 
four patients were still in the hospital at the time of 
the follow-up, and they had no evidence of compli- 
cations. The records of the remaining 40 patients 
were available for review. The mean duration of time 
from the onset of SAB to the latest notation in the 
record for these 40 patients was 34.8 weeks (range, 
3-112 weeks). Ten of the 40 were found to have died, 
but there was no evidence of recurrent SAB or 
S. aureus infection. In the remaining 30 patients, 
there was no evidence of recurrent SAB, metastatic 
infection, or other complications. 
Mortality directly due to MRSAB (42%) was not 
significantly different from that due to MSSAB 
(28%). Mortality secondary to community-acquired 
SAB (31%) was similar to that due to hospital- 
acquired SAB (32%). The mortality due to SAB in 
patients without an identifiable focus (43%) was 
higher than in those with a primary focus (28%), 
but this difference was not significant. The mortal- 
ity rate directly due to SAB in patients younger than 
60 years was 25 % and that in those 60 years or older 
was 35%/ (P > .10). The rates of mortality due to SAB 
in patients with various underlying diseases were as 
follows: alcoholism (29%), malignant solid tumors 
(41%), coronary artery disease (38%0), chronic renal 
failure (43%), cirrhosis (35%), diabetes (31%), 
chronic lung disease (50%), and hematologic malig- 
nancies (0%). There was a trend of higher mortality 
due to SAB in patients with three or more underly- 
ing diseases than in those with one or two underly- 
ing diseases (41% vs. 33%), but this difference was 
not statistically significant. 
The relation between the duration of antimicrobial 
therapy and outcome is given in table 6. Almost all 
patients were treated with a single agent. It is appar- 
ent from the data that once a patient received ther- 
apy for at least 14 days, the chance of succumbing 
to infection was minimal; only two (4%) of 51 pa- 
tients who were treated for >14 days died of infec- 
tion. On the other hand, 34 (94%o) of the 36 patients 
who died of SAB had received <14 days of treatment 
at the time of death. TWenty-three (67%) of these 
34 received <7 days of antibiotic therapy at the time 
of death; four patients died before treatment could 
be initiated. With the exclusion of the latter four pa- 
tients, all of the patients who died of SAB were 
receiving antibiotic therapy at the time of death. 
A comparison of several clinical characteristics of 
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Table 6. Relation between duration of treatment and 
outcome of Staphylococcus aureus bacteremia in 106 
patients. 
No. of patients (mean ? SD) 
receiving treatment for 
indicated period 
Outcome <14 d >14 d 
Died of infection 4.9 ? 3.5 26 
(n = 34) (n = 2) 
Recovered 9.1 ? 3.1 19.6 ? 5.5 
(n = 21) (n = 49) 
NOTE. Five patients who died of their underlying diseases 
during treatment were excluded. 
the 49 patients who recovered after >14 days of ther- 
apy and the 34 patients who died after <14 days of 
therapy was performed. In patients who died dur- 
ing the first 2 weeks of therapy, there were signifi- 
cantly more infections due to MRSA (38% vs. 180%; 
P < .05 by x2) and infections in which no focus was 
identified (26% vs. 10%; P = .05). There was no 
significant difference between the two groups in re- 
gard to mean age, mean number of underlying dis- 
eases, frequency of specific foci of infection, fre- 
quency of community-acquired SAB, or hospital 
service. In the group of patients who received <14 
days of antibiotic treatment, a comparison of the 
clinical characteristics of those who died of SAB and 
those who recovered was performed. The only sig- 
nificantly different characteristic was the frequency 
of catheter-associated SAB: 62% of all infections in 
those who recovered were catheter-associated vs. 
32% in those who died (P < .05). 
Literature Review 
Studies Published Between 1940 and 1960 
Table 7 lists selected findings of studies of SAB pub- 
lished between 1940 and 1960. In 1941 Skinner and 
Keefer [5] published the Boston City Hospital ex- 
perience with SAB over 7 years. This study was rep- 
resentative of SAB in the preantibiotic era. The mor- 
tality rate was 82%; however, most patients in this 
study received no antimicrobial therapy. 
In 1957 Wilson and Hamburger [6] reported an 
analysis of 55 cases of staphylococcal bacteremia t 
the Cincinnati General Hospital (five patients had 
bacteremia due to coagulase-negative staphylococci) 
that occurred between 1940 and 1954. The 64% rate 
of endocarditis in this study is the highest rate re- 
ported secondary to SAB. Twenty-four (69%) of the 
35 patients with endocarditis had underlying valvu- 
lar heart disease. As a result of the high rate of en- 
docarditis reported in this study, it became dogma 
that all patients with SAB should receive prolonged 
(6-week) antimicrobial therapy [32]. However, such 
a general approach based on these data may not have 
been entirely appropriate, given the high rate of un- 
derlying valvular heart disease in the study popula- 
tion. A more appropriate conclusion might have been 
that the risk of endocarditis in patients with valvu- 
Table 7. Selected aspects of studies of Staphylococcus aureus bacteremia (SAB) published between 1941 and 1960. 
Years of No. Community- Patients with Patients with Mortality Deaths 
study of acquired endocarditis complications rate due to 
[reference] cases cases (%) Primary focus, % (%7) (%0) (%7) SAB (%) 
1933-1940 [5] 122 ? Skin, 47; lung, 25; bone, 9; 5.7 82 82 NS 
genitourinary tract, 9; 
unknown, 10 
1940-1954 [6] 55 100 NS 64 38 71 NS 
1940-1956 [8] 109 NS NS * 11 34 NS 
1936-1955 [10] 338 NS NS 7 NS 78 72 
1951-1958 [9] 100 50 Skin, 21; lung, 21; post- 8 NS 64 NS 
operative, 22; genito- 
urinary, 17 
1957-1958 [7] 201 48 Skin, 32; lung, 5 NS NS 41 NS 
1950-1957 [11] 86 53 Skin, 23; intravascular 15 NS 58 NS 
catheter, 23; lung, 17; 
unknown, 16 
NOTE. NS = not stated. 
* Cases of endocarditis excluded. 
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Table 8. Selected findings of studies of Staphylococcus aureus bacteremia (SAB) published between 1961 and 1976. 
Years of No. Community- Patients with Patients with Mortality Deaths 
study of acquired endocarditis complications rate due to 
[reference] cases cases (%) Primary focus, % (%) (%) (%) SAB (%) 
1952-1965 [12] 185* 52 Skin, 35; wound, 18; 6 35 42 NS 
lung, 9; intravascular 
catheter, 6 
1957-1966 [13] 2,027 38 Skin, 20; lung, 5; 3 NS 43 NS 
unknown, 40 
1969-1971 [14] 42 31 NS 14 NS 47 NS 
1969-1973 [15] 105 54 NS 25 44 21 36 
NOTE. NS = not stated. 
* Twenty-five cases were due to coagulase-negative staphylococci. 
lar heart disease and SAB is high and that such pa- 
tients should be treated as if they have endocarditis. 
In patient populations without a high rate of valvu- 
lar heart disease, such as that described by Skinner 
and Keefer [5], the rate of endocarditis was consider- 
ably lower. 
Faber et al. [7] published a report of 201 episodes 
of SAB collected from 86 Danish hospitals in 1957 
and 1958. Forty-one percent of the patients died. This 
study documented a higher mortality rate for hos- 
pital-acquired SAB (55%) than for community-ac- 
quired SAB (28%). Shirger et al. [8] reviewed the 
Mayo Clinic experience with 109 episodes of SAB 
without endocarditis from 1940 to 1956. The mor- 
tality rate in this study (34%) was lower than that 
reported by Skinner and Keefer [5] and Wilson and 
Hamburger [6], probably because patients with en- 
docarditis were excluded, metastatic complications 
were uncommon, and all patients received some type 
of antimicrobial therapy. 
Waisbren and Abboud [9] reviewed 100 cases of 
SAB that occurred at the Milwaukee County General 
Hospital between 1951 and 1958. Although primary 
foci were similar to those reported in previous studies 
and the rate of endocarditis was low (8%), the mor- 
tality rate was high (64%). It was not clear from the 
data presented why the mortality rate was so high, 
given that effective antimicrobial therapy was per- 
formed and few patients had endocarditis. 
Smith and Vickers [10] reported 338 cases of SAB 
at the University Hospitals in Iowa City between 1936 
and 1955. The 19-year period of this study is the lon- 
gest of any published study since 1940. In 87 patients 
who received no antimicrobial treatment, the mor- 
tality rate was 90%, whereas in the 251 who received 
antimicrobial therapy, the mortality rate was 55%. 
An interesting finding made by these authors was 
that the introduction of a new effective agent led to 
an initial decrease in mortality, but with continued 
use resistance occurred and efficacy was lost. 
Hassall and Rountree [11] reviewed 86 episodes of 
SAB that occurred between 1950 and 1957 at a large 
teaching hospital in Australia. In the patients with 
hospital-acquired SAB, the commonest primary fo- 
cus was an iv infusion (20 of 40 episodes). This ap- 
pears to be one of the earliest observations of the 
risk of SAB secondary to infected iv catheters. Un- 
fortunately, the criteria used to identify a catheter 
as the source of SAB were not stated. 
Several conclusions can be made from the studies 
published during the period 1940-1960. First, with 
or without antimicrobial therapy, the mortality rate 
usually exceeded 50%, except in one study [8] in 
which cases of endocarditis were excluded. Second, 
~50% of episodes of SAB were due to community- 
acquired infection. Third, other than the excessively 
high rate of endocarditis reported by Wilson and 
Hamburger [6], the rate of endocarditis was remark- 
ably similar among the studies. Fourth, there was 
close agreement in all studies in regard to common 
primary foci of SAB. However, the finding of a high 
rate of iv-catheter infection by Hassall and Roun- 
tree [11] was a noteworthy exception and was a har- 
binger of the high rate of iv-catheter-associated SAB 
observed in the 1970s and early 1980s. 
Studies Published Between 1961 and 1976 
Cluff and colleagues [12] reported 185 episodes of 
SAB seen at the Johns Hopkins Hospital from 1952 
to 1965 (table 8). This was the second study to em- 
phasize intravascular catheters as a major cause of 
SAB. Despite the higher frequency of underlying dis- 
eases in this study than in the previous studies, the 
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mortality was considerably lower. This was proba- 
bly related, in part, to the availability of semisyn- 
thetic penicillin resistant to i-lactamase as well as 
to continuing improvements in patient care. 
Jessen et al. [13] reported on 1,935 patients with 
SAB (essentially all Danish cases of staphylococcal 
bacteremia) that occurred during 1957-1966 (table 
8). There was a high rate of hospital-acquired SAB 
(62%). The overall mortality rate of 43% and the 
4% rate of endocarditis were remarkably similar to 
those reported by Cluff et al. [12] in the United States 
during almost the same period. 
Austin and Wallace [14] retrospectively reviewed 
42 cases of SAB at the University of Washington 
Hospital in Seattle from 1 January 1969 to 1 Sep- 
tember 1971 (table 8). They studied children as well 
as adults. In comparison to several studies [12, 15] 
of SAB in the same period, the frequency of 
community-acquired SAB (31% of all cases) was 
lower. All cases of endocarditis occurred in associa- 
tion with community-acquired SAB. It is important 
to note that these authors provided information sug- 
gesting that the duration of SAB in community- 
acquired infection was considerably longer than that 
of hospital-acquired SAB (median of 5 days vs. 1 
day). They concluded that this difference in dura- 
tion of SAB was a major factor in the high rate of 
endocarditis among the patients with community- 
acquired SAB. These authors also pointed out that 
in the absence of endocarditis, duration of therapy 
need not exceed 3 weeks. This statement was counter 
to the recommendation that all patients with SAB 
required 4-6 weeks of antimicrobial therapy because 
of the high risk of endocarditis [6, 29]. 
A frequently quoted study is that of Nolan and 
Beaty [15] (table 8). These authors reviewed 105 cases 
of SAB at the Harborview Medical Center in Seat- 
tle, Washington, between 1969 and 1973. It is 
noteworthy that 53% of community-acquired cases 
occurred in iv-drug abusers. In contrast to the low 
rate of endocarditis reported in previous studies (ex- 
cept the study by Wilson and Hamburger [6]), No- 
lan and Beaty reported a rate of 25%, but the over- 
all mortality rate was only 21%, a considerable 
decrease from the 43%o reported by Cluff et al. [12]. 
A major point made by Nolan and Beaty [15] was 
that most of the cases of endocarditis occurred in 
patients with community-acquired SAB in which no 
primary focus could be identified. From these find- 
ings the authors concluded that community-acquired 
SAB occurring in the absence of a primary focus was 
associated with a high risk of endocarditis. However, 
this conclusion was influenced by the fact that two- 
thirds of their cases of community-acquired SAB as- 
sociated with endocarditis occurred in drug abusers. 
This particular patient population is well known to 
have SAB without a primary focus [33, 34]. Thus, 
the findings of Nolan and Beaty may not necessar- 
ily apply to a population without drug abusers. 
Nolan and Beaty also suggested that the lower 
mortality rate reported was due to the availability 
of effective antibiotics and to other factors. How- 
ever, SAB in drug addicts with or without endocardi- 
tis has a good prognosis [33-35]. This factor, cou- 
pled with the large number of drug addicts in this 
study, would tend to make the prognosis better than 
that observed in other investigations in which few 
or no drug abusers were studied. On the other hand, 
Nolan and Beaty suggested that patients with a de- 
fined focus of SAB and no secondary foci may not 
require prolonged (4- to 6-week) antibiotic therapy 
since the risk of endocarditis appeared to be low in 
this group. This was similar to the recommendation 
made by Austin and Wallace [14]. 
The findings in this second era of publications 
concerned with SAB can be summarized as follows. 
An improvement in overall survival was noted, but 
mortality in older patients (i.e., >50 years old) re- 
mained high (>40%). The risk of endocarditis related 
to SAB remained in the range of 5%-10% (exclud- 
ing the study of Nolan and Beaty [15]). There was 
again recognition and further emphasis that the iv 
catheter was an important focus of SAB [12]. This 
observation set the stage for a continuing debate of 
the risk of endocarditis in patients with catheter- 
induced SAB [31, 36, 37]. Nolan and Beaty [15] also 
emphasized that SAB in the subset of patients with 
a defined focus without metastatic infection can be 
treated with 2-3 weeks of antibiotic therapy rather 
than 4-6 weeks. Finally, Nolan and Beaty [15] put 
forth the concept that community-acquired SAB 
without a focus of infection was associated with a 
significant risk of endocarditis. As previously men- 
tioned, this conclusion may have been biased by the 
large number of drug addicts in their study. 
Studies Published Since 1976 
Results of studies published since 1976 are summa- 
rized in table 9. Shah and Watanakunakorn [16] up- 
dated the experience with SAB at the Cincinnati 
General Hospital and contrasted it with the earlier 
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Table 9. Selected findings in studies of Staphylococcus aureus bacteremia (SAB) published since 1976. 
Years of No. Community- Patients with Patients with Mortality Deaths 
study of acquired endocarditis complications rate due to 
[reference] cases cases (%) Primary focus, %7 (%) (%o) (o) SAB (7o) 
1975-1977 [16] 134 40 Skin, 31; intravascular 16 NS 30 20 
catheter, 18; lung, 13; 
bone, 6; unknown, 26 
1977-1980 [17] 61 46 Intravascular catheter, 21; 20 NS 36 NS 
ulcer, 13; wound, 13; 
bone, 5; skin, 5 
1976-1979 [18] 76 54 Skin, 32; intravascular 33 53 41 NS 
catheter, 22; bone, 11; 
lung, 8; unknown, 22 
1978-1980 [19] 49 31 Skin, 10; intravascular 4.3 NS 24 15 
catheter, 29; bone, 10; 
unknown, 22 
1976-1980 [20] 169 41 Wounds + intravascular 11 11 NS 17 
catheter, 50 
1969-1983 [21] 400 30 Intravascular catheter, 23; 7 NS 24 13 
wound, 20; shunt, 14; 
skin, 14 
1980-1981 [22] 39 13 Intravascular catheter, 51; 0 36 30 11 
unknown, 10; shunt, 15 
1979-1982 [23] 103 38 Intravascular catheter, 25; 14 23 43 NS 
skin, 41; lung, 3 
1977-1981 [24] 390 NS Intravascular catheter, 10; 5 NS 31 16 
lung, 19; skin, 7; 
wound, 9; unknown, 32 
1965-1982 [25] 248 100 NS 31 NS NS 19 
NOTE. NS = not stated. 
report from the same hospital by Wilson and Ham- 
burger [6]. Twenty patients (16%) developed en- 
docarditis; 13 of the 20 patients with endocarditis 
acquired SAB in the community, and eight of these 
13 were iv-drug abusers. Of note is that four (18%) 
of 22 patients with iv-catheter-associated SAB de- 
veloped endocarditis; this is the highest rate reported 
for this particular subgroup. Mortality was signifi- 
cantly greater for patients over age 50 years (51%) 
than for those 50 years or younger (13%). The ma- 
jor differences between this report and that of Wil- 
son and Hamburger [6] were that the mortality rate 
was considerably lower (71% vs. 30%) and the rate 
of endocarditis decreased fourfold (65/o vs. 16%). 
The main reason for the decrease in the rate of en- 
docarditis, in our opinion, was the smaller number 
of patients with rheumatic valvular disease in the 
study by Shah and Watanakunakor [16] than in that 
of Wilson and Hamburger (38% vs. 2%o) [6]. 
Cooper and Platt [17] reported the experience with 
SAB at the New England Deaconess Hospital (Bos- 
ton) between August 1977 and August 1980. Since 
this hospital is the principal admitting institution for 
the Joslin Diabetes Foundation, the authors com- 
pared SAB in diabetics with that in nondiabetics. Of 
the 61 patients with SAB, 27 (44%) were diabetic. 
As a result of the predominance of diabetics in the 
study population, infections of foot ulcers and os- 
teomyelitis were frequent primary foci of SAB. How- 
ever, infected iv catheters were the single commonest 
focus. Endocarditis occurred in 20% of all episodes 
of SAB; 11 of the 12 episodes of endocarditis were 
community acquired. Six episodes of endocarditis 
occurred in the absence of an identifiable primary 
focus; the remaining six episodes occurred in patients 
with a primary focus, and all six were diabetics. Only 
one episode of endocarditis occurred among 13 pa- 
tients with iv-catheter-induced SAB. Comparing di- 
abetics and nondiabetics, the authors found no 
difference in mortality, but diabetics with SAB were 
more likely to have endocarditis in the presence of 
a primary focus. 
Several important points were made by Cooper 
and Platt in the discussion of their findings. They 
noted that the 36% overall mortality was higher than 
that in other studies (21% in the study of Nolan and 
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Beaty [15]). These authors, however, also pointed out 
that 20%o f their patients with SAB had metastatic 
cancer and a considerable proportion had other de- 
bilitating diseases. Thus, there would be a tendency 
toward a higher overall mortality rate in this study 
than in studies of patients with a favorable progno- 
sis, e.g., drug addicts [35]. They also noted that en- 
docarditis occurred in patients both with and with- 
out a primary focus. However, one must be cautious 
in the interpretation of this finding. All cases of en- 
docarditis related to a primary focus occurred in the 
diabetic group. Five of the six cases of endocarditis 
in diabetics were related to chronic infection in a dis- 
tal extremity. Cooper and Platt [17] were careful to 
point this out. Thus, this study suggested that dia- 
betics with chronic, indolent infections of distal ex- 
tremities may be at increased risk for complications 
such as endocarditis and probably should receive a 
prolonged (at least 4- to 6-week) course of antibi- 
otic therapy. The results of the study supported the 
concepts that patients with community-acquired 
SAB without a focus are at risk for endocarditis and 
that those with iv-catheter-induced SAB have a min- 
imal risk of endocarditis. 
Mirimanoff and Glauser [18] reviewed 76 cases of 
SAB at the University Medical Center in Lausanne, 
Switzerland, between January 1976 and July 1979. 
It is important to note that 53% of the episodes of 
SAB were associated with metastatic complications 
and 33% of the patients developed endocarditis. The 
rate of endocarditis in patients without a primary 
focus (12 of 17; 71%) was significantly greater than 
the rate in those with an identifiable focus (13 of 59; 
22%7o). However, one-half of the cases of endocardi- 
tis were associated with a primary focus. Only one 
(6%) of 16 patients with intravascular catheter-in- 
duced SAB developed endocarditis. As in other 
studies mortality was significantly lower in patients 
50 years old or younger (7%) than in those older than 
50 years (47%). Unlike previous studies in which high 
rates of endocarditis were found in populations with 
significant risk factors for developing endocarditis, 
e.g., valvular heart disease [6] or drug addiction [15], 
the population studied by Mirimanoff and Glauser 
[18] did not have these predisposing factors present. 
The explanation for the high rate of endocarditis in 
their study is unclear. Nevertheless, this study again 
verified the considerable risk of endocarditis in pa- 
tients without a primary focus of SAB but also sug- 
gested that patients with a defined focus were at risk. 
Mylotte et al. [19] prospectively evaluated 47 pa- 
tients with 49 consecutive episodes of SAB at two 
institutions between September 1978 and June 1980. 
Complications were uncommon: only two patients 
(4.3%) developed endocarditis, and metastatic in- 
fection was also infrequent. Of importance was that 
29% of the episodes of SAB were related to infected 
iv catheters. In this subgroup of patients, endocardi- 
tis was not recognized and no patients died of SAB. 
Mortality rates were lower than those in other studies 
with similar patient populations [16, 22, 24]. 
Hedstrom and Christensson [20] retrospectively 
reviewed 169 cases of SAB that occurred at the 
University Hospital in Lund, Sweden, from 1976 to 
1980. The findings, in terms of the types of primary 
foci of SAB and rates of endocarditis and mortality, 
were similar to those in other studies recently 
reported. Gransden and colleagues [21] prospectively 
evaluated 400 patients with SAB at a hospital in Lon- 
don, England. The findings in regard to the primary 
foci of SAB and rates of endocarditis and mortality 
were remarkably similar to those in other studies 
published since 1976. 
Libman and Arbeit [22] reported a study of 37 
patients with 39 episodes of SAB at the Boston Vet- 
erans Administration Medical Center between De- 
cember 1980 and November 1981. In contrast to 
previous tudies, the majority (87%o) f episodes.were 
hospital acquired. Infected iv catheters produced 
51% of the episodes, a much higher proportion than 
in any previous study. No patients with endocardi- 
tis were identified. This was probably related to the 
high frequency of iv-catheter-induced infections, 
which are known to have a good prognosis and a 
low risk of endocarditis [17-19, 31, 36]. On the other 
hand, metastatic complications occurred in 23% of 
the episodes, including those in four patients with 
catheter-associated SAB. However, in three of the 
four patients with catheter-associated SAB and 
metastatic infection, antibiotic therapy was delayed 
for 48-72 hours after blood cultures were obtained. 
This group with delayed therapy also had prolonged 
bacteremia (median duration, 4 days). Thus, it is not 
surprising that metastatic infection occurred in this 
group. The mortality rate directly due to SAB (30%) 
was in agreement with our previous report [19] in 
a similar patient population. 
Finkelstein and colleagues [23] reviewed the find- 
ings in 103 cases of SAB that occurred in a university 
hospital in Israel between January 1979 and Decem- 
ber 1982. No cases of endocarditis were recognized 
in those patients with SAB secondary to infected iv 
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catheters. All but one patient with endocarditis had 
community-acquired SAB without a primary focus. 
The development of endocarditis in association with 
community-acquired SAB without a primary focus, 
a finding also reported by Mirimanoff and Glauser 
[18], supported the view of Nolan and Beaty [15] con- 
cerning the increased risk of endocarditis in this sub- 
group with SAB without the confounding factor of 
drug abuse. The disconcerting aspect of this study 
was the high mortality rate in patients with endo- 
carditis (64%) and the much higher overall rate of 
mortality (43%) due to SAB than that reported in 
other recent studies (see table 9 [38]). The explana- 
tion for the excessive mortality in this study is not 
readily apparent. 
Bryan and colleagues [24] retrospectively reviewed 
390 consecutive episodes of SAB in four nonuniver- 
sity hospitals in Columbia, South Carolina, between 
January 1977 and December 1981. Endocarditis was 
related predominately to community-acquired SAB. 
Of note was that 26% of 35 patients with iv-catheter- 
induced SAB died. Although the findings in this 
study are in agreement with those in many previous 
studies in regard to the risk of endocarditis and mor- 
tality, one must be cautious in the interpretation of 
the data. Although not stated specifically in this 
study of SAB, Brenner and Bryan [39] and Bryan 
and colleagues [40] described in detail the four hospi- 
tals that were surveyed. These included a commu- 
nity hospital without a house staff and a Veterans 
Administration hospital. The combination of find- 
ings from various nonuniversity hospitals may not 
necessarily give a true picture of SAB. This is espe- 
cially true when one combines data from a Veterans 
Administration hospital in which an elderly male 
population predominates with data from a commu- 
nity hospital with a more balanced population in 
terms of age. 
Julander [25] retrospectively reviewed 273 patients 
with SAB with and without endocarditis who were 
admitted to a hospital for infectious diseases in 
Stockholm, Sweden. Unlike most other studies, 
which generally deal with a general hospital popu- 
lation, this study dealt with data from a specialized 
hospital. Thus, there may be a tendency for more 
complications in this setting. Also, 35% of the pa- 
tients were drug addicts. Since this subgroup with 
a background of drug abuse is at increased risk for 
the development of endocarditis in the presence of 
SAB [15], it is not surprising that 31% of the patients 
had endocarditis. 
Several trends are recognized in studies of SAB 
published since 1976. First, SAB has become pre- 
dominately a hospital-acquired infection. Second, 
infected iv catheters have become a prominent cause 
of SAB. However, the risk of endocarditis associated 
with iv-catheter-induced SAB was minimal except 
in one study [16]. Third, the rate of endocarditis was 
variable, with reported rates from 4% to 33%. In 
several studies [15, 18, 23] endocarditis occurred most 
commonly in the setting of community-acquired 
SAB without a primary focus. Fourth, there was no 
marked change in the mortality due to SAB com- 
pared with that in the previous period analyzed. 
Since most patients developing SAB have significant 
underlying diseases, and since potent antistaphylo- 
coccal therapy has been available for some time, there 
may be little or no further decrease in mortality. 
Discussion 
The findings in the current report can be summa- 
rized as follows. In the setting of a Veterans Adminis- 
tration medical center, SAB was predominately a 
hospital-acquired infection; the commonest source 
of SAB was an infected intravascular catheter; en- 
docarditis and metastatic infection were infrequent, 
each occurring in <5% of all cases; and mortality 
directly related to SAB was high (32%). These find- 
ings are remarkably similar to those at the Boston 
VAMC reported by Libman and Arbeit [22]. 
One of the objectives of our study was to examine 
the risk of endocarditis in patients with community- 
acquired SAB without a definite focus of infection. 
Since only six of the 114 episodes were in this cate- 
gory, it was not possible to make any valid conclu- 
sions about the risk of endocarditis in this group 
from our data. However, on the basis of the find- 
ings of other studies [15, 18, 23], one must be con- 
cerned about the possibility of an increased risk of 
endocarditis in this subgroup of patients with SAB. 
Until more prospective studies are reported in which 
the risk of endocarditis is carefully examined in a 
large number of patients with community-acquired 
SAB, one must rely on the available information and 
strongly consider prolonged (4- to 6-week) parenteral 
antimicrobial therapy in this group of patients. 
Along these lines, Bayer et al. [41] have recently pub- 
lished in abstract form the results of a prospective 
survey of patients with SAB at the Harborview- 
UCLA Medical Center. Using multivariate logistic 
analysis, the authors reported that several variables - 
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including community-acquired SAB and the absence 
of a primary focus-significantly predicted endo- 
carditis. Details concerning the population studied 
were not given; therefore, the importance of these 
observations awaits full publication of their findings. 
In the present study there were 23 episodes (20%) 
of SAB in which the focus of infection was not iden- 
tified. In other published reports of SAB, 10%-400% 
of all episodes of SAB had no identifiable focus (ta- 
bles 7-9). Of the 23 episodes of SAB in the present 
study, 17 (74%) were hospital-acquired infections. 
Despite close evaluation of these patients, no defi- 
nite focus could be verified. It is possible that some 
episodes were related to infection of intravascular 
catheters that were undetected because of lack of 
signs of infection or failure to culture catheters. How- 
ever, the source of SAB in this subgroup remains un- 
clear. 
It is possible that some patients in the present 
study who died had endocarditis or metastatic in- 
fection that was unrecognized. On the other hand, 
most of the patients who died had hospital-acquired 
SAB (31 of 36; 86%) and were promptly treated. We 
believe that this would tend to decrease the rate of 
complications. In addition, factors known to pre- 
dispose to nosocomial endocarditis, e.g., rheumatic 
valvular disease and prosthetic valves [42], were not 
present in our population to any great extent. 
Nevertheless, because few autopsies were performed, 
the rate of endocarditis may be underestimated in 
the present study. 
It is also possible that some patients who com- 
pleted a planned course of therapy for SAB had en- 
docarditis or metastatic infection that was unrecog- 
nized but successfully treated. However, this is 
unlikely in our opinion. The mean duration of ther- 
apy in our patients who recovered was 16.4 days. It 
has been found that patients with S. aureus en- 
docarditis treated for <4 weeks have a high likeli- 
hood of relapse [15]. Thus, one would have expected 
some relapses on follow-up in those who initially re- 
covered. However, no relapses occurred among 40 
patients with a mean duration of follow-up of 34.8 
weeks after completion of treatment. 
We believe it is now clear that there is a low risk 
of endocarditis in patients with SAB related to an 
infected intravascular device if there is prompt 
rerroval of the infected device and antibiotic treat- 
ment. The findings in the present report as well as 
in several others [17-21, 31, 36] have verified this. 
Thus, for patients with intravascular device-related 
SAB, we currently recommend 2 weeks of parenteral 
antimicrobial therapy along with removal of the de- 
vice. However, it should be kept in mind that a small 
number of patients with catheter-associated SAB 
have been reported in whom complications other 
than endocarditis have developed during or after 
therapy [18, 22, 29]. It appears that such cases are 
the exception rather than the rule. In at least one 
study [22], delay in initiating therapy and prolonged 
bacteremia may have been factors that increased the 
risk of complications. Nevertheless, such complica- 
tions have not always been clinically detectable early 
in the course. Therefore, Rahal et al. [43] have re- 
cently suggested a 4-week regimen (iv antibiotic ther- 
apy for 2 weeks followed by oral therapy for 2 weeks) 
as an alternative to short-course therapy (2 weeks 
of parenteral therapy) for patients with SAB due to 
a removable focus of infection or localized infection, 
e.g., skin. In our experience ([19], present report) the 
necessity to extend the duration of therapy beyond 
14 days for catheter-associated SAB or SAB with a 
defined focus is infrequent. However, we agree with 
Rahal et al. [43] that if the clinical situation is such 
that host response is altered, e.g., the presence of 
malignancy, immunosuppression, delayed recogni- 
tion of infection, or persistent bacteremia or fever, 
it would be prudent to prolong therapy beyond 2 
weeks. In this situation the 4-week regimen suggested 
by Rahal et al. [43] is a reasonable approach. 
It is of concern that infections of intravascular 
devices have become the single commonest cause of 
SAB at our institution as well as at other hospitals 
[21-23]. Theoretically, most of these infections are 
preventable if catheters are cared for properly [44]. 
There is evidence that a team dedicated to insertion 
and care of iv catheters can have an impact on the 
infection rate [45]. However, a major problem is rec- 
ognition of catheter infection. In the case of infec- 
tion of catheters in peripheral vessels, infection is 
often associated with phlebitis that is readily detect- 
able clinically. Recognition of infection of central 
venous catheters is more problematic since evidence 
of inflammation at the insertion site is uncommon 
because of the depth of the subclavian vein below 
the skin [46]. This observation is confirmed in the 
present study in which no infected subclavian vein 
catheters had associated inflammation at the inser- 
tion site. This finding emphasizes the importance of 
considering an intravascular catheter as the source 
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of sepsis or bacteremia even in the absence of local 
signs of infection. 
Despite the lack of recognizable complications of 
SAB in our population, the mortality rate of 32%o 
due to infection is disconcerting. There are several 
explanations for this finding. First, our hospital 
population is an elderly one for the most part; the 
mean age of patients with SAB was 64 years. It has 
been previously reported in several studies of SAB 
that patients in this older age group have a poorer 
prognosis than do younger individuals [12, 13, 16, 
18, 23, 24]. Second, some patients with MRSA bac- 
teremia did not receive vancomycin initially, and this 
was associated with a higher mortality than that of 
patients treated with vancomycin, a finding that has 
also been previously described [47]. Third, almost 
all of our patients had one or more significant un- 
derlying diseases that may, to various degrees, have 
impacted on the response to infection. 
Review of the literature dealing with SAB in the 
general hospital setting indicated variation in the 
reported rate of endocarditis, metastatic complica- 
tions, and mortality. This variability points out the 
necessity for caution in interpreting the findings of 
a particular study as being representative of what 
one might find in all hospital populations. This vari- 
ability is exemplified by two studies [14, 15] that re- 
vealed considerably different frequencies of commu- 
nity-acquired SAB, rates of endocarditis, and 
mortality (see table 8) yet were done in the same geo- 
graphic area and during approximately the same 
period. 
Variability in the rate of endocarditis may also be 
related to the criteria used to make this diagnosis. 
Review of the criteria used in each study revealed 
some differences, especially in the literature before 
1960. In these earlier studies, however, the diagno- 
sis of endocarditis was confirmed by autopsy in many 
instances. In almost all studies of SAB published 
since 1960, the criteria for the diagnosis of endocardi- 
tis were clearly stated. On examination of the rates 
of endocarditis reported in the studies listed in ta- 
bles 7-9, one finds that all but four studies [6, 15, 
18, 25] reported a rate of endocarditis of 420% and 
most were in the range of 5%-15%. In three of the 
four studies in which the rate of endocarditis ex- 
ceeded 20%, the patient population consisted, in 
part, of those with an increased risk of endocardi- 
tis - either drug addicts [15, 25] or those with valvu- 
lar heart disease [6]. The report of Mirimanoff and 
Glauser [18] stands alone as the only study in which 
a rate of endocarditis exceeding 20% was found with 
no predisposing risk factors for endocarditis. If these 
four studies are excluded, the rate of endocarditis 
reported in association with SAB has actually been 
fairly constant for the past 45 years. 
MRSA bacteremia has become endemic at the 
Buffalo VAMC since introduction of the index case 
in June 1982 (authors' unpublished data). This in- 
dex case was unusual in that the patient was hospital- 
ized for several weeks before development of MRSA 
bacteremia. Previous studies of MRSA have empha- 
sized that the patient with the index case was usu- 
ally transferred from another hospital or had a 
community-acquired infection [48, 49]. An excep- 
tion was presented in the recent report by Rimland 
[50] in which the index case of MRSA infection was 
acquired or developed in the hospital. The persis- 
tence of MRSA as a cause of bacteremia at the 
Buffalo VAMC is characteristic of this pathogen [51]. 
The mortality rate of 32% in patients with MRSA 
bacteremia treated with vancomycin was similar to 
that found in a study by Craven et al. [52]. Other 
reports [49] have demonstrated a lower mortality rate, 
but the patients with MRSA bacteremia were youn- 
ger than our patients and those of Craven et al. [52]. 
The mortality rate in our patients with MRSA bac- 
teremia not treated with vancomycin was higher than 
in those receiving vancomycin, a phenomenon that 
has also been previously reported [47]. 
In summary, several conclusions can be drawn 
from analysis of studies of SAB. (1) Intravenous- 
catheter infection has become the commonest cause 
of SAB but is associated with a low risk of endocardi- 
tis; effective therapy includes prompt catheter 
removal and parenteral antibiotic therapy for 2 
weeks. (2) Endocarditis is a frequent complication 
of SAB in the drug addict and in patients with val- 
vular heart disease; such patients should be treated 
as if endocarditis is present regardless of signs and 
symptoms. (3) The risk of endocarditis appears to 
be high in patients with community-acquired SAB 
without a definable focus; in this situation it seems 
prudent to advise antibiotic treatment for 4-6 weeks. 
(4) In the absence of clinical risk factors for en- 
docarditis, impaired host response, or infections 
known to require prolonged therapy (e.g., osteomye- 
litis), patients with SAB due to defined foci (other 
than intravascular catheters) can be effectively 
treated for 2-3 weeks with parenteral antibiotics. At 
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present, we recommend parenteral therapy in the hos- 
pital setting, where patients can be monitored for 
complications. 
Addendum 
Subsequent to the acceptance of this manuscript for 
publication, the complete report by Bayer et al. of 
data previously available only in abstract form [41] 
was published [53]. Seventy-two patients with SAB 
at the Harbor-UCLA Medical Center were followed 
prospectively between 1980 and 1984. An unknown 
number of patients with SAB during the study period 
were excluded. Thus, although the study was 
prospective, the population evaluated represented 
only a subset of all patients with SAB. This factor 
makes results difficult to interpret. For example, al- 
though the site of acquisition of SAB is not clearly 
stated, it appears that the majority of cases were 
community acquired. Patient-selection criteria and 
the presence of drug addicts in the patient popula- 
tion probably produced this predominance of 
community-acquired cases. As we have pointed out 
(table 9), in the studies published since 1976 from 
institutions in the United States, SAB has been 
predominately nosocomial in origin. Thus, it is not 
surprising that the results in terms of endocarditis 
compared favorably with those of Nolan and Beaty 
[15] in which the patient population with SAB was 
very similar. Nevertheless, the study of Bayer et al. 
provided evidence that two-dimensional echocardi- 
ography may be useful in identifying endocarditis 
in patients with community-acquired SAB with a pri- 
mary focus. In concurrence with many previous 
studies and the present one, endocarditis was not as- 
sociated with SAB secondary to an infected intravas- 
cular catheter. 
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